Free tool
FAERS Monitor: Epipen E Z Pen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019430 or its brand name (Epipen E Z Pen, Epinephrine). Reports on generic versions are filed under their own applications.
Reports
65,115
Serious
37,014
57% of reports
Hospitalization
17,948
Death reported
4,036
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective5,929
- headache4,422
- fatigue4,074
- sinusitis4,052
- dyspnoea3,477
- nausea3,396
- pain3,365
- product dose omission issue3,247
- off label use2,904
- pneumonia2,668
- covid-192,631
- cough2,285
- pyrexia2,232
- nasopharyngitis2,208
- pruritus2,186
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 160 |
| 2005 | 146 |
| 2006 | 167 |
| 2007 | 233 |
| 2008 | 352 |
| 2009 | 360 |
| 2010 | 536 |
| 2011 | 1,018 |
| 2012 | 819 |
| 2013 | 713 |
| 2014 | 1,430 |
| 2015 | 2,554 |
| 2016 | 6,749 |
| 2017 | 3,571 |
| 2018 | 3,419 |
| 2019 | 4,195 |
| 2020 | 7,414 |
| 2021 | 4,941 |
| 2022 | 4,661 |
| 2023 | 4,945 |
| 2024 | 5,804 |
| 2025 | 6,158 |
| 2026 | 4,767 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,989,044 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sinusitisSignal | 4,052 | 13.3 | 12.9 | 44,302 |
| covid-19Signal | 2,631 | 4.9 | 4.7 | 8,114 |
| nasopharyngitisSignal | 2,208 | 3.9 | 3.7 | 4,751 |
| product dose omission issueSignal | 3,247 | 3.6 | 3.5 | 6,099 |
| pneumoniaSignal | 2,668 | 2.7 | 2.6 | 2,818 |
| coughSignal | 2,285 | 2.6 | 2.5 | 2,349 |
| headacheSignal | 4,422 | 2.3 | 2.2 | 3,278 |
| pyrexiaSignal | 2,232 | 2.1 | 2.0 | 1,282 |
| dyspnoea | 3,477 | 2.0 | 1.9 | 1,748 |
| pruritus | 2,186 | 1.8 | 1.8 | 852 |
| pain | 3,365 | 1.8 | 1.7 | 1,163 |
| fatigue | 4,074 | 1.7 | 1.6 | 1,196 |
| drug ineffective | 5,929 | 1.5 | 1.4 | 896 |
| nausea | 3,396 | 1.4 | 1.3 | 380 |
| off label use | 2,904 | 1.1 | 1.0 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.